TriSalus forecasts 2026 revenue of $46 million to $48 million
TLSI•TriSalus Life Sciences forecasts full-year 2026 revenue of $46 million to $48 million. It cites growth opportunities in an estimated $2.5 billion U.S. device market and says office-based lab reimbursement begins January 1, 2027.
1. 2026 revenue forecast
TriSalus Life Sciences forecasts full-year 2026 revenue of $46 million to $48 million. The company cites deeper liver embolization penetration, new applications and product launches as growth opportunities in an estimated $2.5 billion U.S. device market.
2. Reimbursement timing
Office-based lab reimbursement begins January 1, 2027, expanding access to the company’s pressure-enabled drug delivery technology.
